Deep Intelligent Pharma (DIP) closed a $50 million Series D round to scale an AI platform that its founders say automates clinical trial design and execution. The Singapore-based company will use proceeds to iterate an autonomous clinical system and expand its commercialization network, with the financing led by CDH Baifu and participation from Xinding Capital and HongShan Capital. DIP describes its technology as breaking clinical development into 10,000 “atomic agents” to verify eligibility, simulate endpoints, and reduce design and execution noise. The company claims industrial-grade accuracy and an absence of hallucination problems that commonly afflict generic large-language models. DIP cited a case with Japanese cancer vaccine developer Immunorock, where the platform reportedly produced a PMDA-ready protocol with zero revisions. The funding targets rapid productization and global rollout in a highly regulated space; DIP will face regulatory and validation hurdles as it seeks to translate simulation-led gains into real-world trial performance. Leadership framed the platform as a tool to raise asset success probabilities by front-loading rigorous endpoint simulation and compliance checks.